Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-228 (a Catalytic TORC1/2 Inhibitor) as Single Agent in Adult East Asian Patients With Advanced Nonhematological Malignancies

Next Previous
X
Search
Trial Profile

A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-228 (a Catalytic TORC1/2 Inhibitor) as Single Agent in Adult East Asian Patients With Advanced Nonhematological Malignancies

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sapanisertib (Primary)
  • Indications Advanced breast cancer; Biliary cancer; Bladder cancer; Cervical cancer; Cholangiocarcinoma; Colon cancer; Endometrial cancer; Gallbladder cancer; Gastrointestinal stromal tumours; Head and neck cancer; Male breast cancer; Neuroendocrine carcinoma; Oesophageal cancer; Pancreatic cancer; Periampullary cancer; Peritoneal cancer; Prostate cancer; Rectal cancer; Renal cancer; Sarcoma; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Calithera Biosciences

    • Most Recent Events

    • 29 Nov 2021 Results assessing the safety, tolerability, pharmacokinetics, preliminary efficacy, and to establish the recommended phase 2 dose (RP2D) of sapanisertibpublished in the Targeted Oncology
    • 20 Aug 2020 Status changed from completed to discontinued.
    • 23 Oct 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top